Basic Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 7, 2025; 31(1): 101198
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.101198
Loss-of-function mutations of microRNA-142-3p promote ASH1L expression to induce immune evasion and hepatocellular carcinoma progression
Xing-Hui Yu, Yan Xie, Jian Yu, Kun-Ning Zhang, Zhou-Bo Guo, Di Wang, Zhao-Xian Li, Wei-Qi Zhang, Yu-Ying Tan, Li Zhang, Wen-Tao Jiang
Xing-Hui Yu, Kun-Ning Zhang, Zhao-Xian Li, Wei-Qi Zhang, Wen-Tao Jiang, School of Medicine, Nankai University, Tianjin 300192, China
Xing-Hui Yu, Yan Xie, Yu-Ying Tan, Wen-Tao Jiang, Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Center Hospital, Tianjin 300192, China
Yan Xie, Li Zhang, Wen-Tao Jiang, Department of Liver Transplantation, Tianjin First Center Hospital, Tianjin 300192, China
Jian Yu, Zhou-Bo Guo, Di Wang, First Central Clinical School, Tianjin Medical University, Tianjin 300192, China
Author contributions: Yu XH, Xie Y, and Jiang WT conceived and designed the study; Yu XH, Yu J, Zhang KN, and Guo ZB performed the experimental part; Yu XH, Wang D and Li ZX contributed to data analysis; Yu XH wrote the paper; Zhang WQ, Zhang L, Tan YY, and Jiang WT reviewed and edited the manuscript; Jiang WT is the corresponding author; All authors have read and approved the final manuscript.
Supported by the Haihe Laboratory of Cell Ecosystem Innovation Fund, No. 22HHXBJC00001; and the Key Discipline Special Project of Tianjin Municipal Health Commission, No. TJWJ2022XK016.
Institutional review board statement: The research involving human participators were retrospected and approved by the Ethics Committee of Tianjin First Central Hospital, protocol number: YC-BY-LC-2023-038.
Institutional animal care and use committee statement: The animal experiment was approved by the Animal Experiment Ethics Committee of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, protocol number: IRM/2-IACUC-2408-027.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The authors confirm that the data supporting the findings of this study are available within the article and as its supplementary materials.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wen-Tao Jiang, MD, PhD, Chief Doctor, School of Medicine, Nankai University, No. 94 Weijin Road, Nankai District, Tianjin 300192, China. jiangwentao@nankai.edu.cn
Received: September 7, 2024
Revised: September 28, 2024
Accepted: November 14, 2024
Published online: January 7, 2025
Processing time: 93 Days and 7.9 Hours
Core Tip

Core Tip: This article mainly focuses on the new targets which may be beneficial to treat and predict hepatocellular carcinoma. We would like to shed light on the effects of microRNA-142-3p and ASH1L on the hepatocellular carcinoma cell bioactivity and prognosis of hepatocellular carcinoma patients. Based on the experiments, loss function of microRNA-142-3p induces cancer progression and immune evasion through upregulation of ASH1L in hepatocellular carcinoma. Both microRNA-142-3p and ASH1L can feature as new biomarker for hepatocellular carcinoma in the future. In-depth comprehensive research is indispensable to completely clarity the ASH1L pathology and relevant molecular mechanisms in hepatocellular carcinoma progression.